Abstract
The most abundant microRNA (miRNA) in the liver, miR-122, is regulated by specific, liver-enriched transcription factors and is responsible for proper proliferation and differentiation of hepatocytes and for the regulation of lipid and cholesterol metabolisms. miR-122 is also involved in several hepatic disorders, as downregulation of miR-122 is often associated with hepatocellular carcinoma (HCC) and miR-122 is a required component for the replication and proliferation of the hepatitis C virus (HCV). Various probes have been developed to promote a better understanding of the involvement of miR-122 in liver diseases, including modified antisense agents and small molecule inhibitors. These agents, capable of specifically modifying miR-122 activity, provide excellent tools to investigate the function and regulation of miR-122 and offer potential new lead compounds for drug discovery. Especially small molecule modifiers can display numerous advantages over nucleotide analogs, as discussed in this review.
Keywords: miRNA-122, liver disorders, miRNA therapeutics, small molecules, antisense oligonucleotides, antagomirs, hepatitis C virus, hepatocellular carcinoma, lipid and cholesterol metabolism, regulation of miRNA function.
Current Medicinal Chemistry
Title:MicroRNA miR-122 as a Therapeutic Target for Oligonucleotides and Small Molecules
Volume: 20 Issue: 29
Author(s): M. Thomas and A. Deiters
Affiliation:
Keywords: miRNA-122, liver disorders, miRNA therapeutics, small molecules, antisense oligonucleotides, antagomirs, hepatitis C virus, hepatocellular carcinoma, lipid and cholesterol metabolism, regulation of miRNA function.
Abstract: The most abundant microRNA (miRNA) in the liver, miR-122, is regulated by specific, liver-enriched transcription factors and is responsible for proper proliferation and differentiation of hepatocytes and for the regulation of lipid and cholesterol metabolisms. miR-122 is also involved in several hepatic disorders, as downregulation of miR-122 is often associated with hepatocellular carcinoma (HCC) and miR-122 is a required component for the replication and proliferation of the hepatitis C virus (HCV). Various probes have been developed to promote a better understanding of the involvement of miR-122 in liver diseases, including modified antisense agents and small molecule inhibitors. These agents, capable of specifically modifying miR-122 activity, provide excellent tools to investigate the function and regulation of miR-122 and offer potential new lead compounds for drug discovery. Especially small molecule modifiers can display numerous advantages over nucleotide analogs, as discussed in this review.
Export Options
About this article
Cite this article as:
Thomas M. and Deiters A., MicroRNA miR-122 as a Therapeutic Target for Oligonucleotides and Small Molecules, Current Medicinal Chemistry 2013; 20 (29) . https://dx.doi.org/10.2174/0929867311320290009
DOI https://dx.doi.org/10.2174/0929867311320290009 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Is Type 2 Diabetes Mellitus a Predisposal Cause for Developing Hepatocellular Carcinoma?
Current Diabetes Reviews Stem Cell Transplantation in Pediatric Leukemia and Myelodysplasia: State of the Art and Current Challenges
Current Stem Cell Research & Therapy Modulation of Huntington’s Disease in Drosophila
CNS & Neurological Disorders - Drug Targets NBS1 Heterozygosity and Cancer Risk
Current Genomics Synthesis and Anticancer Activity of Some 1H-inden-1-one Substituted (Heteroaryl)Acetamide Derivatives
Letters in Drug Design & Discovery Redox Homeostasis, Bioactive Agents and Transduction Therapy
Current Signal Transduction Therapy Synthetic 2-Methoxyestradiol Derivatives: Structure-Activity Relationships
Current Medicinal Chemistry Decreasing Systemic Toxicity Via Transdermal Delivery of Anticancer Drugs
Current Drug Metabolism A Review of Recent Advancements in Anti-tubercular Molecular Hybrids
Current Medicinal Chemistry <i>In Silico</i> Docking Studies of Vascular Endothelial Growth Factor-A (VEGFA): Possible Implications in Chronic Myeloid Leukemia (CML) Therapy
Current Proteomics Myelodysplastic Syndromes: Review of Pathophysiology and Current Novel Treatment Approaches
Current Cancer Drug Targets Immune Checkpoint Inhibitors in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Case Report and Literature Review
Current Cancer Drug Targets Targeting p73 - a Potential Approach in Cancer Treatment
Current Pharmaceutical Design RNA Binding Protein/RNA Element Interactions and the Control of Translation
Current Protein & Peptide Science Survey of Recent Literature Related to the Biologically Active 4(3H)-Quinazolinones Containing Fused Heterocycles
Current Medicinal Chemistry Meet Our Editorial Board Member
Current Medicinal Chemistry The Development of MetAP-2 Inhibitors in Cancer Treatment
Current Medicinal Chemistry Apoptosis Induction by Erucylphosphohomocholine via the 18 kDa Mitochondrial Translocator Protein: Implications for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Significance of Various Experimental Models and Assay Techniques in Cancer Diagnosis
Mini-Reviews in Medicinal Chemistry Caffeic Acid Phenethyl Ester Effects: In Silico Study of its Osteoimmunological Mechanisms
Letters in Drug Design & Discovery